AC
RXDX

Aaron Cowen’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Aaron Cowen’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-480,480
Closed -$11.4M – 121
2021
Q3 		$11.4M Sell
480,480
-145,145
-23% -$3.43M 0.19% 65
2021
Q2 		$15.4M Buy
625,625
+47,091
+8% +$1.05M 0.23% 66
2021
Q1 		$10.6M Buy
+578,534
New +$11.9M 0.16% 74

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Aaron Cowen's RXDX Position: Q4 2021 in Review

Aaron Cowen sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2021, closing a stake of 480,480 shares — an estimated $11.4M sold.

Aaron Cowen first reported a position in RXDX in Q1 2021 and held it in 3 quarters. The position peaked at $15.4M in Q2 2021. 74 funds tracked by Wall St. Rank hold RXDX as of Q4 2021.

  • Aaron Cowen reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Aaron Cowen sold 480,480 Prometheus Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $11.4M.
  • Aaron Cowen first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Aaron Cowen's Prometheus Biosciences, Inc. Common Stock position peaked at $15.4M in Q2 2021.
  • 74 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2021.

Based on Suvretta Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.